LinkedIn Profile

Access Abeona Therapeutics historical Linkedin company profile data on number of followers, employee headcount and more

Rows

Open dataset
Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Headcount change in past 24 months Company Name Sector Industry
nasdaq:abeo 140013 May 5th, 2024 12:00AM Abeona Therapeutics 14K 112.00 Open May 4th, 2024 10:38PM May 4th, 2024 10:38PM Abeona Therapeutics (Nasdaq: ABEO) is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. The Company’s multi-platform expertise across the manufacture, delivery, development, and discovery of novel gene and cell therapies has it uniquely positioned for success. Underpinning the Company’s robust pipeline is its fully-operational manufacturing facility producing therapies and vectors for preclinical and clinical studies. Abeona is also developing the AIM™ Vector Platform: 100+ next-generation AAV capsids for delivering gene therapies targeting a wide range of organs and multiple routes of delivery. A robust and diverse pipeline is led by a novel gene-corrected cell therapy poised to enter Phase 3 in mid-2019 and complemented by one-time gene therapy candidates across four lysosomal storage diseases. Several preclinical discoveries are led by an emerging program in cystic fibrosis that uses the AIM vector platform and a capsid that has shown potential across inherited and acquired retinal diseases. Open Gene Therapy, Infantile Batten Disease, Biotechnology, Cell Therapy, Rare Disease, Epidermolysis Bullosa, Lysosomal Storage Disease, Sanfiippo Syndrome Type A, Sanfiippo Syndrome Type B, juvenile Batten Disease, Pediatric Rare Diseases, and manufacturing Open 1330 Avenue of the Americas New York NY US 10019 Abeona Therapeutics
nasdaq:abeo 140013 May 4th, 2024 12:00AM Abeona Therapeutics 14K 112.00 Open May 3rd, 2024 10:33PM May 4th, 2024 06:14PM Abeona Therapeutics (Nasdaq: ABEO) is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. The Company’s multi-platform expertise across the manufacture, delivery, development, and discovery of novel gene and cell therapies has it uniquely positioned for success. Underpinning the Company’s robust pipeline is its fully-operational manufacturing facility producing therapies and vectors for preclinical and clinical studies. Abeona is also developing the AIM™ Vector Platform: 100+ next-generation AAV capsids for delivering gene therapies targeting a wide range of organs and multiple routes of delivery. A robust and diverse pipeline is led by a novel gene-corrected cell therapy poised to enter Phase 3 in mid-2019 and complemented by one-time gene therapy candidates across four lysosomal storage diseases. Several preclinical discoveries are led by an emerging program in cystic fibrosis that uses the AIM vector platform and a capsid that has shown potential across inherited and acquired retinal diseases. Open Gene Therapy, Infantile Batten Disease, Biotechnology, Cell Therapy, Rare Disease, Epidermolysis Bullosa, Lysosomal Storage Disease, Sanfiippo Syndrome Type A, Sanfiippo Syndrome Type B, juvenile Batten Disease, Pediatric Rare Diseases, and manufacturing Open 1330 Avenue of the Americas New York NY US 10019 Abeona Therapeutics
nasdaq:abeo 140013 May 3rd, 2024 12:00AM Abeona Therapeutics 14K 112.00 Open May 2nd, 2024 10:28PM May 3rd, 2024 01:59PM Abeona Therapeutics (Nasdaq: ABEO) is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. The Company’s multi-platform expertise across the manufacture, delivery, development, and discovery of novel gene and cell therapies has it uniquely positioned for success. Underpinning the Company’s robust pipeline is its fully-operational manufacturing facility producing therapies and vectors for preclinical and clinical studies. Abeona is also developing the AIM™ Vector Platform: 100+ next-generation AAV capsids for delivering gene therapies targeting a wide range of organs and multiple routes of delivery. A robust and diverse pipeline is led by a novel gene-corrected cell therapy poised to enter Phase 3 in mid-2019 and complemented by one-time gene therapy candidates across four lysosomal storage diseases. Several preclinical discoveries are led by an emerging program in cystic fibrosis that uses the AIM vector platform and a capsid that has shown potential across inherited and acquired retinal diseases. Open Gene Therapy, Infantile Batten Disease, Biotechnology, Cell Therapy, Rare Disease, Epidermolysis Bullosa, Lysosomal Storage Disease, Sanfiippo Syndrome Type A, Sanfiippo Syndrome Type B, juvenile Batten Disease, Pediatric Rare Diseases, and manufacturing Open 1330 Avenue of the Americas New York NY US 10019 Abeona Therapeutics
nasdaq:abeo 140013 May 2nd, 2024 12:00AM Abeona Therapeutics 14K 112.00 Open May 1st, 2024 10:36PM May 2nd, 2024 09:33AM Abeona Therapeutics (Nasdaq: ABEO) is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. The Company’s multi-platform expertise across the manufacture, delivery, development, and discovery of novel gene and cell therapies has it uniquely positioned for success. Underpinning the Company’s robust pipeline is its fully-operational manufacturing facility producing therapies and vectors for preclinical and clinical studies. Abeona is also developing the AIM™ Vector Platform: 100+ next-generation AAV capsids for delivering gene therapies targeting a wide range of organs and multiple routes of delivery. A robust and diverse pipeline is led by a novel gene-corrected cell therapy poised to enter Phase 3 in mid-2019 and complemented by one-time gene therapy candidates across four lysosomal storage diseases. Several preclinical discoveries are led by an emerging program in cystic fibrosis that uses the AIM vector platform and a capsid that has shown potential across inherited and acquired retinal diseases. Open Gene Therapy, Infantile Batten Disease, Biotechnology, Cell Therapy, Rare Disease, Epidermolysis Bullosa, Lysosomal Storage Disease, Sanfiippo Syndrome Type A, Sanfiippo Syndrome Type B, juvenile Batten Disease, Pediatric Rare Diseases, and manufacturing Open 1330 Avenue of the Americas New York NY US 10019 Abeona Therapeutics
nasdaq:abeo 140013 May 1st, 2024 12:00AM Abeona Therapeutics 14K 112.00 Open Apr 30th, 2024 11:11PM May 1st, 2024 09:00AM Abeona Therapeutics (Nasdaq: ABEO) is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. The Company’s multi-platform expertise across the manufacture, delivery, development, and discovery of novel gene and cell therapies has it uniquely positioned for success. Underpinning the Company’s robust pipeline is its fully-operational manufacturing facility producing therapies and vectors for preclinical and clinical studies. Abeona is also developing the AIM™ Vector Platform: 100+ next-generation AAV capsids for delivering gene therapies targeting a wide range of organs and multiple routes of delivery. A robust and diverse pipeline is led by a novel gene-corrected cell therapy poised to enter Phase 3 in mid-2019 and complemented by one-time gene therapy candidates across four lysosomal storage diseases. Several preclinical discoveries are led by an emerging program in cystic fibrosis that uses the AIM vector platform and a capsid that has shown potential across inherited and acquired retinal diseases. Open Gene Therapy, Infantile Batten Disease, Biotechnology, Cell Therapy, Rare Disease, Epidermolysis Bullosa, Lysosomal Storage Disease, Sanfiippo Syndrome Type A, Sanfiippo Syndrome Type B, juvenile Batten Disease, Pediatric Rare Diseases, and manufacturing Open 1330 Avenue of the Americas New York NY US 10019 Abeona Therapeutics
nasdaq:abeo 140013 Apr 30th, 2024 12:00AM Abeona Therapeutics 14K 112.00 Open Apr 29th, 2024 10:40PM Apr 30th, 2024 07:51AM Abeona Therapeutics (Nasdaq: ABEO) is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. The Company’s multi-platform expertise across the manufacture, delivery, development, and discovery of novel gene and cell therapies has it uniquely positioned for success. Underpinning the Company’s robust pipeline is its fully-operational manufacturing facility producing therapies and vectors for preclinical and clinical studies. Abeona is also developing the AIM™ Vector Platform: 100+ next-generation AAV capsids for delivering gene therapies targeting a wide range of organs and multiple routes of delivery. A robust and diverse pipeline is led by a novel gene-corrected cell therapy poised to enter Phase 3 in mid-2019 and complemented by one-time gene therapy candidates across four lysosomal storage diseases. Several preclinical discoveries are led by an emerging program in cystic fibrosis that uses the AIM vector platform and a capsid that has shown potential across inherited and acquired retinal diseases. Open Gene Therapy, Infantile Batten Disease, Biotechnology, Cell Therapy, Rare Disease, Epidermolysis Bullosa, Lysosomal Storage Disease, Sanfiippo Syndrome Type A, Sanfiippo Syndrome Type B, juvenile Batten Disease, Pediatric Rare Diseases, and manufacturing Open 1330 Avenue of the Americas New York NY US 10019 Abeona Therapeutics
nasdaq:abeo 140013 Apr 29th, 2024 12:00AM Abeona Therapeutics 14K 112.00 Open Apr 28th, 2024 11:17PM Apr 29th, 2024 09:00AM Abeona Therapeutics (Nasdaq: ABEO) is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. The Company’s multi-platform expertise across the manufacture, delivery, development, and discovery of novel gene and cell therapies has it uniquely positioned for success. Underpinning the Company’s robust pipeline is its fully-operational manufacturing facility producing therapies and vectors for preclinical and clinical studies. Abeona is also developing the AIM™ Vector Platform: 100+ next-generation AAV capsids for delivering gene therapies targeting a wide range of organs and multiple routes of delivery. A robust and diverse pipeline is led by a novel gene-corrected cell therapy poised to enter Phase 3 in mid-2019 and complemented by one-time gene therapy candidates across four lysosomal storage diseases. Several preclinical discoveries are led by an emerging program in cystic fibrosis that uses the AIM vector platform and a capsid that has shown potential across inherited and acquired retinal diseases. Open Gene Therapy, Infantile Batten Disease, Biotechnology, Cell Therapy, Rare Disease, Epidermolysis Bullosa, Lysosomal Storage Disease, Sanfiippo Syndrome Type A, Sanfiippo Syndrome Type B, juvenile Batten Disease, Pediatric Rare Diseases, and manufacturing Open 1330 Avenue of the Americas New York NY US 10019 Abeona Therapeutics
nasdaq:abeo 140013 Apr 28th, 2024 12:00AM Abeona Therapeutics 14K 112.00 Open Apr 27th, 2024 10:38PM Apr 27th, 2024 10:38PM Abeona Therapeutics (Nasdaq: ABEO) is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. The Company’s multi-platform expertise across the manufacture, delivery, development, and discovery of novel gene and cell therapies has it uniquely positioned for success. Underpinning the Company’s robust pipeline is its fully-operational manufacturing facility producing therapies and vectors for preclinical and clinical studies. Abeona is also developing the AIM™ Vector Platform: 100+ next-generation AAV capsids for delivering gene therapies targeting a wide range of organs and multiple routes of delivery. A robust and diverse pipeline is led by a novel gene-corrected cell therapy poised to enter Phase 3 in mid-2019 and complemented by one-time gene therapy candidates across four lysosomal storage diseases. Several preclinical discoveries are led by an emerging program in cystic fibrosis that uses the AIM vector platform and a capsid that has shown potential across inherited and acquired retinal diseases. Open Gene Therapy, Infantile Batten Disease, Biotechnology, Cell Therapy, Rare Disease, Epidermolysis Bullosa, Lysosomal Storage Disease, Sanfiippo Syndrome Type A, Sanfiippo Syndrome Type B, juvenile Batten Disease, Pediatric Rare Diseases, and manufacturing Open 1330 Avenue of the Americas New York NY US 10019 Abeona Therapeutics
nasdaq:abeo 140013 Apr 27th, 2024 12:00AM Abeona Therapeutics 14K 112.00 Open Apr 26th, 2024 10:29PM Apr 26th, 2024 10:29PM Abeona Therapeutics (Nasdaq: ABEO) is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. The Company’s multi-platform expertise across the manufacture, delivery, development, and discovery of novel gene and cell therapies has it uniquely positioned for success. Underpinning the Company’s robust pipeline is its fully-operational manufacturing facility producing therapies and vectors for preclinical and clinical studies. Abeona is also developing the AIM™ Vector Platform: 100+ next-generation AAV capsids for delivering gene therapies targeting a wide range of organs and multiple routes of delivery. A robust and diverse pipeline is led by a novel gene-corrected cell therapy poised to enter Phase 3 in mid-2019 and complemented by one-time gene therapy candidates across four lysosomal storage diseases. Several preclinical discoveries are led by an emerging program in cystic fibrosis that uses the AIM vector platform and a capsid that has shown potential across inherited and acquired retinal diseases. Open Gene Therapy, Infantile Batten Disease, Biotechnology, Cell Therapy, Rare Disease, Epidermolysis Bullosa, Lysosomal Storage Disease, Sanfiippo Syndrome Type A, Sanfiippo Syndrome Type B, juvenile Batten Disease, Pediatric Rare Diseases, and manufacturing Open 1330 Avenue of the Americas New York NY US 10019 Abeona Therapeutics
nasdaq:abeo 140013 Apr 26th, 2024 12:00AM Abeona Therapeutics 14K 112.00 Open Apr 25th, 2024 10:37PM Apr 26th, 2024 07:56AM Abeona Therapeutics (Nasdaq: ABEO) is a fully-integrated gene and cell therapy company at the forefront of the rapidly-advancing field of genetic medicine. The Company’s multi-platform expertise across the manufacture, delivery, development, and discovery of novel gene and cell therapies has it uniquely positioned for success. Underpinning the Company’s robust pipeline is its fully-operational manufacturing facility producing therapies and vectors for preclinical and clinical studies. Abeona is also developing the AIM™ Vector Platform: 100+ next-generation AAV capsids for delivering gene therapies targeting a wide range of organs and multiple routes of delivery. A robust and diverse pipeline is led by a novel gene-corrected cell therapy poised to enter Phase 3 in mid-2019 and complemented by one-time gene therapy candidates across four lysosomal storage diseases. Several preclinical discoveries are led by an emerging program in cystic fibrosis that uses the AIM vector platform and a capsid that has shown potential across inherited and acquired retinal diseases. Open Gene Therapy, Infantile Batten Disease, Biotechnology, Cell Therapy, Rare Disease, Epidermolysis Bullosa, Lysosomal Storage Disease, Sanfiippo Syndrome Type A, Sanfiippo Syndrome Type B, juvenile Batten Disease, Pediatric Rare Diseases, and manufacturing Open 1330 Avenue of the Americas New York NY US 10019 Abeona Therapeutics

Request a demo to view additional historical data, and much more.

Request Demo

Make fast
queries

No longer rely on engineers to access data; build and share queries with intuitive tools, and derive insights in real time.

Bookmark queries with your team

Save and share custom queries using a private bookmarking feature, accessible to your whole team.

Be first to know with alerts

Scan data points across millions of companies and receive emails when relevant metrics cross critical thresholds.

Visualize data for quick insights

Create custom keyword-based word clouds, charts, and advanced visualizations to quickly analyze the data.

Map competitor locations

Analyze competitor presence and growth over time by overlaying store locations with the Nearby Competitor feature.

Add widgets to your dashboards

Access existing maps, charts, word clouds, and other visualizations to understand your data quickly. Or build custom widgets to view data just the way you want it.